Immunovant, Inc. (IMVT)

NASDAQ: IMVT · Real-Time Price · USD
16.02
+0.68 (4.43%)
At close: Jun 5, 2025, 4:00 PM
15.54
-0.48 (-3.00%)
After-hours: Jun 5, 2025, 6:29 PM EDT
4.43%
Market Cap 2.74B
Revenue (ttm) n/a
Net Income (ttm) -413.84M
Shares Out 170.92M
EPS (ttm) -2.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,885,605
Open 15.35
Previous Close 15.34
Day's Range 15.02 - 16.16
52-Week Range 12.72 - 34.47
Beta 0.61
Analysts Buy
Price Target 40.14 (+150.56%)
Earnings Date Aug 5, 2025

About IMVT

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for graves' disease and thyroid eye disease. The company has a license agreement with HanAll Biopharma Co., Ltd. for the rights of intellectual property relating to IMVT-1402 and batoclimab. Immunovant, Inc. wa... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 207
Stock Exchange NASDAQ
Ticker Symbol IMVT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for IMVT stock is "Buy." The 12-month stock price forecast is $40.14, which is an increase of 150.56% from the latest price.

Price Target
$40.14
(150.56% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD) and...

7 days ago - GlobeNewsWire

Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward

Immunovant, Inc. reported that positive results were achieved using batoclimab in a phase 3 study to target patients with Myasthenia Gravis; Primary endpoint met. Positive results achieved using batoc...

2 months ago - Seeking Alpha

Immunovant's muscle disorder treatment meets main goal in late-stage trial

Immunovant said on Wednesday its drug for a type of a chronic autoimmune disease that causes muscle weakness met the main goal in a late-stage trial.

2 months ago - Reuters

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported...

2 months ago - GlobeNewsWire

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...

2 months ago - GlobeNewsWire

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported ...

4 months ago - GlobeNewsWire

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

NEW YORK , Jan. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their f...

4 months ago - PRNewsWire

Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study

Immunovant aims to initiate a pivotal registration study for IMVT-1402 targeting Graves' Disease by the end of 2024, with 4–5 trials in other IgG-mediated autoimmune disorders by March 2025. IMVT-1402...

5 months ago - Seeking Alpha

FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial

Presents Current Treatment Practices, Emerging Drugs, Market Share of Individual Therapies, and FcRn Inhibitor Market Size from 2020 to 2034 Presents Current Treatment Practices, Emerging Drugs, Marke...

6 months ago - GlobeNewsWire

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported ...

7 months ago - GlobeNewsWire

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced...

7 months ago - GlobeNewsWire

Top 2 Health Care Stocks That May Collapse This Quarter

As of Sept. 9, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Other symbols: TERN
9 months ago - Benzinga

Immunovant Provides Update on Graves' Disease Development Program

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported...

9 months ago - GlobeNewsWire

Immunovant to Host Graves' Disease Program Update on September 9, 2024

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...

9 months ago - GlobeNewsWire

Long Assets On Path To Creating Significant Value, Shorting Remains Very Challenging

In the first half of 2024, our long book performed strong relative to the Russell 2000, driven by our high-conviction positions. We are pleased with our relative performance and believe the Russell 20...

10 months ago - Seeking Alpha

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported c...

1 year ago - GlobeNewsWire

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

Immunovant's IMVT-1402 shows promise for at-home autoimmune treatment, with a differentiated subcutaneous delivery. Phase 1 data indicate significant IgG reductions without major side effects, advanci...

1 year ago - Seeking Alpha

Immunovant Awarded U.S. Patent for IMVT-1402

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...

1 year ago - GlobeNewsWire

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023

NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported ...

1 year ago - GlobeNewsWire

Chris DeMuth Sure Likes Uranium And SHF Holdings + 3 Litigation Ideas

Chris DeMuth Jr. discusses his position in uranium and his belief that nuclear energy will play a significant role in the future of energy production. He also updates us on SHF Holdings, a fintech com...

Other symbols: BURLQDA
1 year ago - Seeking Alpha

Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced...

1 year ago - GlobeNewsWire

Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease

NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced...

1 year ago - GlobeNewsWire

Best Small-Cap Stocks to Buy for 2024 and Beyond

Wall Street's best small-cap stocks to buy include pharma, biotech and specialty retail names.

1 year ago - Kiplinger

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) --  Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...

1 year ago - GlobeNewsWire

Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena

Immunovant continues to show promising developments in anti-FcRn platform's clinical trials and has a strong financial position. Key upcoming catalysts, including Phase 1 data and Phase 2 results, cou...

1 year ago - Seeking Alpha